Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent
ACS Pharmacology & Translational Science · 14.11.2025 · 8 (11) · 3757-3772
DOI: 10.1021/acsptsci.5c00502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 03.10.2025. Verfasst von Laura L Demsey und 15 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Epstein Family Foundation.
Themen: Demenz
Abstract (Originalsprache)
Ongoing Alzheimer's disease (AD) drug development research addresses the need for therapeutic agents that can ameliorate cognitive symptoms and attenuate the course of AD synaptic deficits and neurodegeneration. There is growing interest in evaluating FDA-approved drugs for repurposing as candidate AD therapeutics. Such drugs have the advantage that data are available about their pharmaceutical properties, including doses, pharmacokinetics, pharmacodynamics, biomarkers, metabolism, and safety, to inform the design of clinical drug trials. Importantly, the suitability of such drugs with properties needed for AD requires evaluation. In the early stage of AD, degeneration of the locus coeruleus (LC) brain region results in the reduction of noradrenergic neurons and the loss of the neurotransmitter norepinephrine (NE) that regulates cognition and degeneration. Elevation of extracellular NE through inhibition of the NE transporter (NET) is hypothesized to ameliorate AD deficits. Notably, the NET reuptake inhibitor atomoxetine, an FDA-approved drug for the treatment of attention deficit hyperactivity disorder (ADHD), provides an attractive candidate as an AD therapeutic agent because it may attenuate cognitive decline in AD patients, positively impact AD biomarkers, and reduce neuropathology. The goal of this review is to assess atomoxetine for repurposing in AD based on its ability to improve cognition, regulate NE, impact AD biomarkers, and preserve LC neuronal function, with suitable pharmacokinetics, drug metabolism, and safety based on analysis of clinical and preclinical studies. Evidence for neuroprotective effects of atomoxetine in the early stage of AD at clinically safe doses with suitable pharmaceutical properties supports its candidacy as a repurposed drug for AD therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States.
- Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, Georgia 30322, United States.
- Department of Neurology, Emory University, Atlanta, Georgia 30322, United States.
- Department of Human Genetics, Emory University, Atlanta, California 30322, United States.
- Department of Neurosciences and the Alzheimer's Disease Research Center, University of California, San Diego, La Jolla, California 92093, United States.
- The Athinoula Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, United States.
ORCID-Profile: Laura L Demsey, Vivian Hook
Förderung
- NIA NIH HHS
- Epstein Family Foundation
Zitieren
APA
Demsey, L. L., Burch, D., Lin, E., Quach, D., Podvin, S., Boyarko, B., Levey, A. I., Weinshenker, D., Edland, S., Galasko, D., Jacobs, H., Bang, A., Neil, A., Silverman, J., Feldman, H. H., & Hook, V. (2025). Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent. ACS Pharmacology & Translational Science, 8(11), 3757-3772. https://doi.org/10.1021/acsptsci.5c00502
Vancouver
Demsey LL, Burch D, Lin E, Quach D, Podvin S, Boyarko B, et al. Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent. ACS Pharmacology & Translational Science. 2025;8(11):3757-3772. doi:10.1021/acsptsci.5c00502
BibTeX
@article{Demsey2025,
author = {Demsey, Laura L and Burch, Danielle and Lin, Evan and Quach, Diana and Podvin, Sonia and Boyarko, Ben and Levey, Allan I and Weinshenker, David and Edland, Steven and Galasko, Douglas and Jacobs, Heidi and Bang, Anne and Neil, Ashley and Silverman, James and Feldman, Howard H and Hook, Vivian},
title = {Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent},
journal = {ACS Pharmacology & Translational Science},
year = {2025},
volume = {8},
number = {11},
pages = {3757--3772},
doi = {10.1021/acsptsci.5c00502}
}
EUVIMED